Biopharmaceutical company Hutchison China MediTech (Chi-Med) has reported top-line results from its Phase III pivotal registration trial (FRESCO) of fruquintinib (HMPL-013) in 416 patients with locally advanced or metastatic colorectal cancer (CRC) in China.

Fruquintinib is a highly selective, small-molecule drug candidate that has been shown to inhibit VEGFR 24 hours a day via an oral dose.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The randomised, double-blind, placebo-controlled, multicentre trial met its primary endpoint of demonstrating a rise in overall survival (OS), in the intention-to-treat (ITT) population of patients treated with fruquintinib plus best supportive care (BSC).

An improvement in progression-free survival (PFS), a key secondary endpoint, was also observed.

Hutchison China MediTech chairman Simon To said: “The success of the FRESCO trial is an important milestone not just for CRC patients and Chi-Med, but also for Chinese innovation.

"The success of the FRESCO trial is an important milestone not just for CRC patients and Chi-Med, but also for Chinese innovation."

“It shows that China has the resources, capability and perseverance to emerge as an innovator in the global oncology field. With eight small molecule drug candidates in more than 30 clinical studies worldwide, Chi-Med is at the forefront of this important evolution.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In addition to the FRESCO colorectal cancer trial, fruquintinib is being studied in China in a Phase III pivotal trial in non-small-cell lung cancer (NSCLC), known as FALUCA.

The company is also planning other studies and will initiate them soon.

They include a Phase III trial in gastric cancer along with paclitaxel in China, new studies in the US, and other exploratory studies in combination with oncology agents.

About 380,000 new cases of CRC are reported in China every year, according to CA Cancer Journal for Clinicians 2016.